PharmiWeb.com - Global Pharma News & Resources

Marketing - Press Releases

Date Title Company
03-Mar-2020 Acacia Pharma Group plc : Results for the year ended 31 December 2019 Acacia Pharma Group plc
03-Mar-2020 Sensyne Health recognised for its impact in helping treat diabetes in pregnancy Sensyne Health plc
03-Mar-2020 Viroclinics Biosciences and DDL Diagnostic Laboratory Join Forces Viroclinics Biosciences
28-Feb-2020 Merck and AMCM / EOS Cooperate in 3D Printing of Tablets Merck
28-Feb-2020 Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2019 Nordic Nanovector ASA
28-Feb-2020 Coulter Partners secures Chief Scientific Officer for CENTOGENE Coulter Partners
28-Feb-2020 ABPI response to the UK’s approach to EU negotiations The Association of the British Pharmaceutical Industry
28-Feb-2020 Scanning and imaging techniques at the forefront of Lewy body dementia research The Lewy Body Society
28-Feb-2020 Insilico Biotechnology AG opens subsidiary in Boston Insilico Biotechnology AG
28-Feb-2020 Hikma delivers strong growth in revenue and profit in 2019 Hikma
28-Feb-2020 Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study Inflazome
28-Feb-2020 Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV) Acacia Pharma Group plc
28-Feb-2020 Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2019 Nordic Nanovector ASA
28-Feb-2020 iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers iTeos Therapeutics Inc
28-Feb-2020 Update regarding independent review, CEO removal and other matters NMC HEALTH PLC
28-Feb-2020 Nordic Nanovector Appoints Dr Lars Nieba as interim Chief Executive Officer Nordic Nanovector
28-Feb-2020 MSL Insights Management Platform Now Enables MSLs and MSL Teams to Manage Every Step of the Insight Cycle System Analytic
28-Feb-2020 AXON Gets Another Wellbeing Award Nod from Great Place to Work® UK AXON
28-Feb-2020 iOnctura announces first patient dosed in a phase I clinical study of its novel highly selective PI3Kδ inhibitor, IOA-244 for solid tumours iOnctura
28-Feb-2020 NEW RESEARCH REVEALS THE NEED FOR GREATER UNDERSTANDING OF EUROPEAN PHARMACEUTICAL MARKETS TO MAXIMISE DIGITAL STRATEGIES Bryter